TD Cowen raised the firm’s price target on Soleno Therapeutics (SLNO) to $120 from $115 and keeps a Buy rating on the shares. The firm notes Soleno reported impressive Vykat XR revenue of $33M in its first partial quarter and reiterated the 646 PSFs and 295 unique prescribers as of 6/30. Payor support is also proving strong, with a third of insured U.S. lives already covered. TD Cowen remains confident in Vykat XR’s strong value proposition for the PWS community as well as this team’s ability to continue executing on this launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics price target raised to $110 from $105 at Oppenheimer
- Soleno Therapeutics Reports Strong Q2 2025 Performance
- Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand
- Tyler Van Buren Reaffirms Buy Rating with Increased Sales Projections and Price Target for SLNO
- Soleno Therapeutics price target raised to $121 from $105 at Baird